SAN DIEGO, Oct. 26 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company presented its research entitled: DNA-customized Genotrim [neuronal dopamine release activator] results in significant reductions in weight, appetite and sugar cravings in an obese population in the Dietary Investigation to Evaluate Treatments (D.I.E.T.) pilot study. Polymorphic gene correlates of Reward Deficiency Syndrome (RDS) at the Second Bruce Ames International Symposium on Nutritional Genomics last week at the University of California, Davis. Over the past two years, Salugen's research around genetics and weight loss has been repeatedly awarded by the nation's largest natural products association. At this meeting, Dr. Kenneth Blum, Chief Scientific Officer of Salugen discussed the nutrigenomics of weight loss, specifically on identifying the genes and nutrients governing cravings and appetite.
According to Dr. Kenneth Blum, the co-discoverer of the gene associated with alcoholism, "This study demonstrates that GenoTrim, a DNA-customized nutritional supplement for weight management, is a potentially effective agent in reducing weight and improving symptomatic RDS behaviors. We are also proposing that for persons possessing candidate reward gene polymorphisms resulting in physiological deficits in brain reward neurotransmitters, utilizing a dopaminergic type d2 receptor agonist, such as GenoTrim, can activate the neuronal release of dopamine in the nucleus acumbens."
In this study over 80 days, GenoTrim demonstrated significant reductions in weight, waist circumference, appetite, and sugar cravings, as well as improvements in energy, and feelings of happiness.
Salugen CEO Brian Meshkin states, "We are honored to be among so many
other credible researchers from around the world to present important
findings about the use of genetic information to customize nutritional
supplementation that demonstrates weight loss and improved health. This
|SOURCE Salugen, Inc.|
Copyright©2007 PR Newswire.
All rights reserved